Evidence map›Paper›PMID 38384888›Full record

ArticleFrontiers in public health2024

Impact of the COVID-19 pandemic on the prevalence of respiratory viral pathogens in patients with acute respiratory infection in Shanghai, China.

Lifeng Pan, Yang Yuan, Qiqi Cui, Xuechun Zhang, Yujia Huo, Qing Liu, Wenwei Zou, Bing Zhao, Lipeng Hao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Analysis of influenza A, influenza B andFrontiers in public health · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Changing Trends in Paediatric Acute Respiratory Infections:Sultan Qaboos University medical journal · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lifeng Pan *Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Yang Yuan *Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Qiqi CuiShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Xuechun ZhangShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Yujia HuoShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Qing LiuShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Wenwei ZouShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Bing ZhaoShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Lipeng HaoShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Shanghai Municipal Center For Disease Control Prevention · CNChinese Center For Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to evaluate the impact of nonpharmaceutical interventions (NPIs) taken to combat COVID-19 on the prevalence of respiratory viruses (RVs) of acute respiratory infections (ARIs) in Shanghai. Methods: Samples from ARI patients were collected and screened for 17 respiratory viral pathogens using TagMan low density microfluidic chip technology in Shanghai from January 2019 to December 2020. Pathogen data were analyzed to assess changes in acute respiratory infections between 2019 and 2020. Results: A total of 2,744 patients were enrolled, including 1,710 and 1,034 in 2019 and 2020, respectively. The total detection rate of RVs decreased by 149.74% in 2020. However, detection rates for human respiratory syncytial virus B (RSVB), human coronavirus 229E (HCoV229E), human coronavirus NL63 (HCoVNL63), and human parainfluenza virus 3 (HPIV3) increased by 91.89, 58.33, 44.68 and 24.29%, in 2020. The increased positive rates of RSVB, HPIV3, resulted in more outpatients in 2020 than in 2019. IFV detection rates declined dramatically across gender, age groups, and seasons in 2020. Conclusion: NPIs taken to eliminate COVID-19 had an impact on the prevalence of respiratory viral pathogens, especially the IFVs in the early phases of the pandemic. Partial respiratory viruses resurged with the lifting of NPIs, leading to an increase in ARIs infection.

Indexed as

COVID-19Respiratory Tract InfectionsChinaHumansPandemicsPrevalenceacute respiratory infectionCOVID-19nonpharmaceutical interventionsShanghaiviral pathogen

Identifiers

PMID38384888
PMCPMC10880446
OpenAlexW4391602666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.